United Therapeutics (UTHR) Tops Q4 EPS Views; Guides FY13 Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Brean Downgrades United Therapeutics (UTHR) to Hold, Says Price Target Acheived
February 26, 2013 1:10 PM ESTBrean Capital downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Buy to Hold.
"We are downgrading United to Hold from Buy due to the achievement of our target price and our view that the next catalyst, a second FDA action on a refiled oral... More



